Sangamo BioSciences (SGMO) : The consensus on Sangamo BioSciences (SGMO) based on 6 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Sangamo BioSciences (SGMO) : The highest level Sangamo BioSciences (SGMO) is projected to reach is $30 for the short term and the lowest estimate is at $8. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $15.25 and the possibility the share price can swing is $10.18.
Sangamo Biosciences Inc. has lost 2.22% in the last five trading days and dropped 23.61% in the last 4 weeks. Sangamo Biosciences Inc. has dropped 31.99% during the last 3-month period . Year-to-Date the stock performance stands at -51.81%. Sangamo BioSciences (NASDAQ:SGMO): On Tuesdays trading session , Opening price of the stock was $4.45 with an intraday high of $4.495. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.391. However, the stock managed to close at $4.4, a loss of 0.45% for the day. On the previous day, the stock had closed at $4.42. The total traded volume of the day was 495,802 shares.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.